3 completed. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
Follow Altor BioScience: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer ALT-803, Nivolumab - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Medical University of South Carolina | 67 | 2016-01-08 | 2026-02-17 |
| A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Cisplatin, Gemcitabine, ALT-801 - Transitional Cell Carcinoma of Bladder, Urethra Cancer | Phase 1 / Phase 2 | Completed | Altor BioScience | 68 | 2011-09-06 | 2024-06-25 |
| Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome ALT-836, Placebo - Sepsis, Acute Lung Injury | Phase 2 | Completed | Altor BioScience | 150 | 2009-04-01 | 2015-04-10 |
Acute Lung Injury (1) · Carcinoma, Non-Small-Cell Lung (1) · Lung Diseases (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Respiratory Distress Syndrome (1) · Sepsis (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1) · Urinary Bladder Neoplasms (1)
ALT-801 (1) · ALT-803 (1) · ALT-836 (1) · Cisplatin (1) · Gemcitabine (1) · Nivolumab (1)
United States (3)
Hing C Wong, PhD (1) · John Wrangle, MD (1)